Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.
about
Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining IssuesJSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of JapanClinical utility of imaging for evaluation of hepatocellular carcinomaDiagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current ConsensusRecent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRISurveillance, diagnosis, treatment, and outcome of liver cancer in JapanRecent advances in the imaging of hepatocellular carcinomaNatural history of liver imaging reporting and data system category 4 nodules in MRI.Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5.Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology.Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma.Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infectionsThe utility of gadoxetic acid-enhanced MR imaging to characterize atypical cirrhotic nodules detected on dynamic CT images.[Rational imaging of hepatocellular carcinoma. The challenge of multimodal diagnostic criteria].CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging featuresPrognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma.Was Hypervascular Hepatocellular Carcinoma Visible on Previous Gadoxetic Acid-Enhanced Magnetic Resonance Images?The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR imagesNovel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)Optimal timing and diagnostic adequacy of hepatocyte phase imaging with gadoxetate-enhanced liver MRI.Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.Navigated three-dimensional T1-weighted gradient-echo sequence for gadoxetic acid liver magnetic resonance imaging in patients with limited breath-holding capacity.Preoperative gadoxetic Acid-enhanced MRI and simultaneous treatment of early hepatocellular carcinoma prolonged recurrence-free survival of progressed hepatocellular carcinoma patients after hepatic resection.State of the art: hepatocellular carcinoma.Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease.Can combining triple-arterial phase acquisition with fluoroscopic triggering provide both optimal early and late hepatic arterial phase images during gadoxetic acid-enhanced MRI?Ongoing challenges in the diagnosis of hepatocellular carcinoma.LI-RADS(®) ancillary features on CT and MRI.Assessment of clinical and magnetic resonance imaging features of de novo hypervascular hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging.Breakthrough Imaging in Hepatocellular CarcinomaAbnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells.How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis.Early hepatocellular carcinoma as a signaling lesion for subsequent malignancy.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Clinical value of gadoxetic acid-enhanced magnetic resonance imaging in surgery for hepatocellular carcinoma - with a special emphasis on early hepatocellular carcinoma.Performance of gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in recipients of living-related-liver-transplantation: comparison with dynamic multidetector row computed tomography and angiography-assisted computed tomography.IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.Progression of Hepatic Hypovascular Nodules with Hypointensity in the Hepatobiliary Phase of Gd-EOB-DTPA-enhanced MRI in Hepatocellular Carcinoma Cases.Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC.Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.
P2860
Q26770020-837C44B7-2D97-465D-BF2D-E327B8317D2BQ26797521-A5B5078F-0A8C-47BF-A4C3-3F8D15071A39Q26823224-9B0D0316-B840-4909-8C2C-3FF45951384EQ27027855-0E26279A-DF51-4284-908A-525A7BD848A6Q28075361-B7975E47-4D04-42D7-AAC3-9B73454044C2Q28082702-84C9E008-C4E0-4FBF-9E32-4E6EC01F1564Q30415186-8258DF2F-D678-4044-9493-8AAF146477E1Q31090559-28A1C2AB-4D57-4807-93A1-E137A277475DQ31154548-DC7036D0-F551-4F9F-8C4D-E60F38AA3111Q33561375-7905996D-1A1C-43A4-BD55-A3E087FDC142Q33651997-BCC54950-D724-42A8-A0D9-455A2FBB23C9Q33773121-03E491C3-6C96-4426-A4FC-6DCD8457DDC9Q34331579-BD91A70A-20FF-42CA-A9D9-23A733DB9E85Q34663392-9DCBF0F1-93C9-4880-9685-965EE614725DQ34682228-4B1D93A8-577F-40F4-AB6C-3EEC57303937Q36138282-C5F5D659-E4CB-4DE7-8BBF-1E9F22BA044CQ36170512-AA56D18A-4463-42DB-A4AF-752CCDA82314Q36326793-135027EB-54F5-44DF-84FB-85106785AEB9Q36423114-3CD77207-AF49-4D82-9582-302709C60E99Q38203386-4067FC27-B818-40F3-8B33-75F2C2F0119EQ38238010-90CC0E83-37C3-425F-AC97-F12C88EA0487Q38238929-A13A899A-DF5D-4638-AA8B-53D60E1CE1E6Q38255718-4EBF62E8-ED00-4BEA-88A4-BD07D5710312Q38283649-481251D4-9C56-48CC-8CD7-087760618815Q38574812-D865CEA8-E787-4146-9C81-D6F8890878A7Q38607851-2E81F33E-F357-49AE-9B64-D55BD3E3CAC4Q38646886-72168DF1-FBDF-466F-8DFB-D21B992593CDQ38710312-AF9F167F-29F5-4674-9FB6-4C7D104AE29CQ38830332-70AD2BB3-A930-457F-8669-F19F2F053AFCQ38969727-7BCBB7EA-03D2-40CE-AD51-5478FF0FDA2EQ39135542-6FC04BFA-43FC-45E4-957A-0E960C669698Q39381803-BB9A6E1E-E310-425B-9AF9-C246F6375912Q40584888-28E138D8-E198-4EB7-A46D-BF9F9E22CC7CQ41962614-942FB077-AD6C-4251-8E8C-34670650B249Q43115840-8D44DEDC-6FC2-4849-A70E-0B9C92977461Q44043742-81FBF9A7-4D73-42C5-A952-5754ED4FC1A7Q45858225-6D6C8D85-C8F8-4F32-A52D-8F353CD78CB9Q47896669-C87683DB-78FB-44CC-8912-940600687C64Q48622310-66E48A78-1244-4B67-9F6A-0240CF8DB574Q48792736-653CE8F3-11FB-43C7-B68D-76ED7E676579
P2860
Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Hypovascular nodules in patien ...... ular hepatocellular carcinoma.
@en
type
label
Hypovascular nodules in patien ...... ular hepatocellular carcinoma.
@en
prefLabel
Hypovascular nodules in patien ...... ular hepatocellular carcinoma.
@en
P2093
P356
P1433
P1476
Hypovascular nodules in patien ...... ular hepatocellular carcinoma.
@en
P2093
Masahiro Okada
Masatoshi Hori
Sachiyo Kogita
Seishi Kumano
Takamichi Murakami
Teruhito Mochizuki
Yasuharu Imai
Yuki Kagawa
P304
P356
10.1148/RADIOL.12112677
P407
P577
2013-02-01T00:00:00Z